Abstract
Objectives This study used National Health Insurance claims data from Korea to report the prevalence of sleep disorders and treatment status, including traditional Korean medicine, in the last ten years.
Methods This is a retrospective cohort study in Korea. All diagnosis and prescription data, including herbal medicine claims, from the Health Insurance Review and Assessment Service from 2011 to 2020 were reviewed. Prevalence estimation, direct medical expenses, and prescribed amounts for sleep disorders were recorded.
Results The prevalence of sleep disorders increased from 3,867,975 (7.62%) in 2011 to 7,446,846 (14.41%) in 2020, nearly doubling over 10 years. Insomnia was observed in 91.44% (n=9,011,692) of the patients. The mean number of hospital visits per patient for sleep disorders was 11.5 (±26.62). Benzodiazepines are the most commonly prescribed medications for sleep disorders, and gamma-isoyosan is the most frequently prescribed herbal medicine.
Conclusions Sleep disorders are continuously increasing, as is the use of medical services – personal and social medical expenses are also increasing accordingly. Sleep disorders should be recognized as a significant health problem that needs to be actively addressed to improve quality of life.
Strengths and limitations of this study
This is a nationwide health insurance claims data for prevalence and the status of treatment on sleep disorders for ten years.
This study will be meaningful because we have confirmed the current address of the prevalence and treatment of sleep disorders in the last 10 years.
The data source has the limitation of being able to confirm only the items subject to health insurance benefits and review.
The results of tests for the diagnosis of sleep disorders were not confirmed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the grant from Korea Institute of Oriental Medicine (KSN2023120, KSN20234113).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research data were pseudonymized, and provision was determined by the the Health Insurance Review and Assessment Service (HIRA)'s Public Data Provision Deliberation Committee. The study's protocol was also exempted from ethical review by the Institutional Review Board of the Korea Institute of Oriental Medicine (IRB No. I-2107/006-001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
ekahn{at}kiom.re.kr
aori79{at}kiom.re.kr
jepark{at}kiom.re.kr
bfree{at}kiom.re.kr
Data Availability
The data that support the findings of this study are available from the Healthcare Big Data Hub of the HIRA. However, restrictions apply with regard to availability as they were used under license for research in the current study; therefore, these data are not publicly available.
